Abstract Number: 487 • 2016 ACR/ARHP Annual Meeting
Limited Utility of Cytokine Profiles in Rheumatoid Arthritis Patients with Clinically Active Disease and Normal Inflammatory Indices
Methods: RA patients enrolled in a longitudinal observational registry (VARA) were studied and clinical and disease status characteristics documented. Patients with high joint counts (TJC +…Abstract Number: 488 • 2016 ACR/ARHP Annual Meeting
Exploring the Association Between Air Pollutant Exposure and Seropositivity in Rheumatoid Arthritis
Background/Purpose: The etiology of rheumatoid arthritis (RA) is multi-factorial, with expression of HLA-DRB1 shared epitope (SE), smoking and socioeconomic status (SES) exerting influence. Prior studies…Abstract Number: 489 • 2016 ACR/ARHP Annual Meeting
Early Detection of Inflammatory Arthritis: The Role of Musculoskeletal Symptoms, Infections and Rheumatoid Arthritis-Related Comorbidities in Primary Care
ACR ABSTRACT 2016 Early detection of inflammatory arthritis: the role of musculoskeletal symptoms, infections and rheumatoid arthritis-related comorbidities in primary care Background/Purpose: Rheumatoid arthritis…Abstract Number: 490 • 2016 ACR/ARHP Annual Meeting
First Report of Symptoms Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire
Background/Purpose: Persons at risk of rheumatoid arthritis (RA) may experience a variety of symptoms1,2. However, information on location, timing, severity and predictive value of these…Abstract Number: 491 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)
Background/Purpose: Current clinical guidelines recommend testing for anti-citrullinated protein antibodies (ACPA) at the time of RA diagnosis.1 However, there is a lack of information about…Abstract Number: 492 • 2016 ACR/ARHP Annual Meeting
Calprotectin Levels Correlate with Inflammation in Early Rheumatoid Arthritis before Disease-Modifying Antirheumatic Drug Treatment and after 12 Months of Treatment
Background/Purpose: Calprotectin (MRP8/MRP14, S100A8/A9) is a major leukocyte protein previously shown to be associated with disease activity in patients with established rheumatoid arthritis (RA). Some…Abstract Number: 493 • 2016 ACR/ARHP Annual Meeting
The 2010 ACR/EULAR Criteria Are Not Sufficiently Accurate in the Early Identification of Autoantibody-Negative Rheumatoid Arthritis
Background/Purpose: The 2010-ACR/EULAR criteria were derived to classify RA earlier in time. Previous studies indeed observed that the 2010-criteria were fulfilled earlier than the 1987-criteria.…Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…Abstract Number: 495 • 2016 ACR/ARHP Annual Meeting
The Relative Performance of 28-Joint Disease Activity Score Based on C-Reactive Protein with Three Versus Four Components in Patients with Rheumatoid Arthritis
Background/Purpose: The commonly used version of the 28-joint disease activity score based on C-reactive protein (DAS28-CRP4) includes swollen and tender joint counts (S/TJC), CRP and…Abstract Number: 496 • 2016 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
Background/Purpose: RA Patients with anti-citrullinated protein antibody (ACPA) or rheumatoid factor (RF) are known to have worse clinical outcomes compared to seronegative patients. To determine…Abstract Number: 497 • 2016 ACR/ARHP Annual Meeting
The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the American College of Rheumatology (ACR)20 score was developed to best discriminate effective from placebo…Abstract Number: 498 • 2016 ACR/ARHP Annual Meeting
Higher Serum Heavy Metals Concentrations Are Associated with Rheumatoid Arthritis : A Study of the Korean National Health and Nutrition Examination Survey (KNHANES)
Background/Purpose: The heavy metal Cadmium (Cd) may contribute to the high risk of developing rheumatoid arthritis (RA) through the cigarette smoking and occupational exposure including…Abstract Number: 499 • 2016 ACR/ARHP Annual Meeting
High Levels of Mir-451a Differentiate Patients at Risk of Developing RA from Healthy Controls
Background/Purpose: Individuals with clinically suspect arthralgia (CSA) with positivity of antibodies to citrullinated protein antigens (ACPA) have articular symptoms without clinical signs of arthritis. CSA…Abstract Number: 500 • 2016 ACR/ARHP Annual Meeting
Can Thiol/Disulphide Is a Novel Marker in Rheumatoid Arthritis?
Background/Purpose: Rheumatoid arthritis is a chronic, systemic, autoimmune disease about 5% -%1 of world population affected. Highly reactive oxygen free radicals are believed to be…Abstract Number: 501 • 2016 ACR/ARHP Annual Meeting
Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis
Background/Purpose: Anti-cyclic citrullinated peptide antibody (Anti-CCP) is a diagnostic tool that predicts the progression of undifferentiated polyarthritis and erosive disease in rheumatoid arthritis (RA). It…
ACR Meeting Abstracts